Thiazolidinediones may be effective in the prevention of stent thrombosis with DES

Medical Hypotheses

Volumn 70, Issue 2, 2008, Pages 329-332

  Cao, Zheng ^a   Zhou, Yujie ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PIOGLITAZONE; RAPAMYCIN;

ARTICLE; CARDIOVASCULAR RISK; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFICACY; DRUG ELUTING STENT; ENDOTHELIUM CELL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; UPREGULATION;

ANIMALS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HUMANS; MODELS, CARDIOVASCULAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET ACTIVATION; PPAR GAMMA; THIAZOLIDINEDIONES; THROMBOSIS;

EID: 37449022956     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.04.045     Document Type: Article

References (29)

1. Moreno R., Fernandez C., Hernandez R., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 (2005) 954-959
2. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
3. Lüscher T.F., Steffel J., Eberli F.R., et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115 (2007) 1051-1058
4. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin 23 (2007) 945-952
5. Smyth S.S., and Jennings J.L. PPARgamma agonists: a new strategy for antithrombotic therapy. J Thromb Haemost 3 (2005) 2147-2148
6. Hannan K.M., Dilley R.J., Dios S.T., and Little P.J. Troglitazone stimulates repair of the endothelium and inhibits neointimal formation in denuded rat aorta. Arterioscler Thromb Vasc Biol 23 (2003) 762-768
7. Li D., Chen K., Sinha N., et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 65 (2005) 907-912
8. Parry T.J., Brosius R., Thyagarajan R., et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 524 (2005) 19-29
9. Liuzzo J.P., Ambrose J.A., Coppola J.T., et al. Sirolimus- and Taxol-eluting stents differ towards intimal hyperplasia and re-endothelialization. J Invasive Cardio 17 (2005) 497-502
10. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
11. Guagliumi G., Farb A., Musumeci G., et al. Images in cardiovascular medicine: sirolimus-eluting stent implanted in human coronary artery for 16 months: pathological findings. Circulation 107 (2003) 1340-1341
12. Urao N., Okigaki M., Yamada H., et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 98 (2006) 1405-1413
13. Griese D.P., Ehsan A., Melo L.G., et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 108 (2003) 2710-2715
14. Butzal M., Loges S., Schweizer M., et al. Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res 300 (2004) 65-71
15. Pistrosch F., Herbrig K., Oelschlaegel U., et al. PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 183 (2005) 163-167
16. Wang C.H., Ciliberti N., Li S.H., et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation 109 (2004) 1392-1400
17. Inoue T., Hikichi Y., Morooka T., et al. Comparison of changes in circulating platelet-derived microparticles and platelet surface P-selectin expression after coronary stent implantation. Platelets 17 (2006) 416-420
18. Wenaweser P., Dorffler-Melly J., Imboden K., et al. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
19. Bliden K.P., DiChiara J., Tantry U.S., et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. J Am Coll Cardiol 49 (2007) 657-666
20. Akbiyik F., Ray D.M., Gettings K.F., et al. Human bone marrow megakaryocytes and platelets express PPAR-γ, and PPAR-γ agonists blunt platelet release of CD40 ligand and thromboxanes. Blood 104 (2004) 1361-1368
21. Bodary P.F., Vargas F.B., King S.A., et al. Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance. J Thromb Haemost 3 (2005) 2149-2153
22. Vaughan D.E. PAI-1 and atherothrombosis. J Thromb Haemost 3 (2005) 1879-1883
23. Marcucci R., Brogi D., Sofi F., and Giglioli C. PAI-1 and homocysteine, but not lipoprotein (a) and thrombophilic polymorphisms, are independently associated with the occurrence of major adverse cardiac events after successful coronary stenting. Heart 92 (2006) 377-381
24. Eitzman D.T., Westrick R.J., Nabel E.G., et al. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 95 (2000) 577-580
25. Muldowney III J., Stringham J.R., Levy S.E., et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression. A potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol 27 (2007) 400-406
26. Lang N.N., and Newby D.E. Emerging thrombotic effects of drug eluting stents. Arterioscler Throm Vasc Biol 27 (2007) 261-262
27. Freed M., Fuell D., Menci L., et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia 43 (2004) 267-273
28. Zirlik A., Leugers A., Lohrmann J., et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 91 (2004) 674-682
29. Blaschke F., Spanheimer R., Khan M., and Law R.E. Vascular effects of TZDs: New implications. Vascular Pharmacol 45 (2006) 3-18